Wall Street brokerages expect Masimo Co. (NASDAQ:MASI) to announce earnings of $0.61 per share for the current quarter, according to Zacks. Four analysts have made estimates for Masimo’s earnings. The lowest EPS estimate is $0.60 and the highest is $0.62. Masimo reported earnings of $0.51 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 19.6%. The firm is expected to report its next earnings report on Tuesday, February 13th.
On average, analysts expect that Masimo will report full-year earnings of $2.95 per share for the current financial year, with EPS estimates ranging from $2.95 to $2.96. For the next financial year, analysts expect that the company will post earnings of $2.60 per share, with EPS estimates ranging from $2.48 to $2.75. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Masimo.
Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.53 by $0.17. The firm had revenue of $193.69 million during the quarter, compared to analysts’ expectations of $189.01 million. Masimo had a return on equity of 22.17% and a net margin of 45.83%. Masimo’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period last year, the business earned $0.52 earnings per share.
In other news, EVP Yongsam Lee sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $89.89, for a total value of $449,450.00. Following the completion of the sale, the executive vice president now directly owns 74,000 shares in the company, valued at $6,651,860. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Steven Barker sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $90.00, for a total value of $900,000.00. Following the completion of the sale, the director now owns 73,249 shares of the company’s stock, valued at $6,592,410. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,074 shares of company stock valued at $4,737,245. 16.60% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in MASI. DekaBank Deutsche Girozentrale increased its position in Masimo by 78.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock worth $182,000 after purchasing an additional 925 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Masimo by 13.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,018 shares of the medical equipment provider’s stock worth $184,000 after purchasing an additional 236 shares during the period. Advisor Group Inc. increased its position in Masimo by 38.4% in the second quarter. Advisor Group Inc. now owns 2,361 shares of the medical equipment provider’s stock worth $216,000 after purchasing an additional 655 shares during the period. Intellectus Partners LLC acquired a new stake in Masimo in the second quarter worth about $237,000. Finally, Shelton Capital Management bought a new position in Masimo during the second quarter worth about $269,000. Hedge funds and other institutional investors own 83.69% of the company’s stock.
Shares of Masimo (NASDAQ MASI) traded down $0.03 during mid-day trading on Thursday, reaching $87.27. The company had a trading volume of 268,600 shares, compared to its average volume of 600,467. The company has a market capitalization of $4,510.89, a PE ratio of 33.45, a P/E/G ratio of 2.94 and a beta of 0.72. Masimo has a 52-week low of $66.79 and a 52-week high of $104.71.
TRADEMARK VIOLATION NOTICE: This news story was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/21/analysts-anticipate-masimo-co-masi-to-announce-0-61-earnings-per-share.html.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Masimo? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Masimo and related companies.